New Field Cycling Imager scanner shows promise for more accurate breast cancer diagnosis

Researchers at the University of Aberdeen have built a scanner that sees breast tumors differently than the machines hospitals use today. The Field Cycling Imager, or FCI, works by varying the strength of its magnetic field during a scan—essentially functioning as multiple imaging tools in one. In early trials conducted with NHS Grampian, the device distinguished cancerous tissue from healthy tissue with greater precision than conventional MRI, a finding that could reshape how thousands of women are treated for breast cancer each year.

The practical stakes are concrete. About one in seven women who undergo a lumpectomy—surgery to remove a tumor while preserving the breast—require a second operation because surgeons cannot clearly see whether cancer remains at the edges of the wound. The FCI scanner's improved ability to map tumor boundaries could eliminate many of those repeat procedures. For patients, this means fewer surgeries, shorter recovery periods, and less time away from work and family. For the health system, it means operating theaters freed up for other patients and shorter wait lists.

Dr. Lionel Broche, the senior research fellow leading the work, explained that the scanner's capacity to characterize tumors more accurately could improve biopsy procedures and help doctors tailor treatment to each patient's specific cancer type and location. The technology also avoids a problem that plagues current imaging: the need to inject contrast dye into the bloodstream. That dye, while useful for highlighting tissue differences, has been linked to kidney damage and allergic reactions in some patients. The FCI scanner extracts the information it needs without any injection at all.

The device descends from work done at Aberdeen five decades ago, when researchers there built the world's first clinical MRI scanner—a breakthrough that has since saved millions of lives globally. The FCI represents an evolution of that same principle. Where traditional MRI uses strong, constant magnetic fields and radio waves to create images, the FCI's variable field approach reveals tissue properties that standard MRI cannot detect. In the breast cancer study, this difference proved decisive: the scanner identified a secondary tumor that the conventional MRI had missed entirely, a case where the patient carried two different types of tumor and one was simply invisible to the older technology.

Dr. Gerald Lip, a consultant radiologist at NHS Grampian and newly appointed president of the British Society of Breast Radiology, called the results promising but cautious about the timeline. His hospital treats between 400 and 500 women with breast cancer annually. If the FCI technology proves itself in larger, prospective studies—the next phase of research—the reduction in repeat surgeries alone could transform the patient experience and ease pressure on surgical schedules. Lip noted that the potential impact extends beyond individual cases: fewer repeat operations mean fewer complications, shorter overall treatment timelines, and the ability to redirect resources to other patients waiting for care.

The research, published in Nature Communications Medicine, represents an early-stage success. The team is continuing to refine the technology, and Broche emphasized that clinical applications could eventually extend far beyond breast cancer. For now, the focus remains on proving the FCI's value in the specific context where it has already shown promise—helping surgeons see what they need to see the first time, so patients do not have to come back.